skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15295

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations



Review

(5992) Total Article Views


Authors: Emilio Rintaro Suzuki Jr, Cibele Lima Belico Suzuki

Published Date October 2010 Volume 2010:4 Pages 1165 - 1171
DOI: http://dx.doi.org/10.2147/OPTH.S6289

Emilio Rintaro Suzuki Jr, Cibele Lima Belico Suzuki
Instituto de Olhos Pampulha, Belo, Horizonte, Minas Gerais, Brazil

Abstract: Travoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and timolol can reach even greater IOP reductions than fixed combinations at some time points, but with no difference in the early morning, when IOP is usually higher. In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the vision or health of the patient. The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma.

Keywords: travoprost, prostaglandin, glaucoma

Corrigendum




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Emilio Suzuki Jr.


Readers of this article also read: